What is Genialis, Inc?
Genialis, Inc. operates at the vanguard of the techbio sector, specializing in precision oncology. The company addresses the persistent challenges of patient variability and high clinical trial failure rates by integrating sophisticated AI models with deep biological insights. Their core technology, the Genialis Supermodel, serves as a robust framework for therapeutic intelligence, enabling pharmaceutical developers to better predict drug efficacy and safety profiles. By transforming complex multiomics data into actionable clinical insights, Genialis is effectively reducing the risk profile of oncology drug development, thereby facilitating the transition of promising molecules into life-saving treatments.
How much funding has Genialis, Inc raised?
Genialis, Inc has raised a total of $15.3M across 2 funding rounds:
Angel/Seed
$2.3M
Series A
$13M
Angel/Seed (2017): $2.3M with participation from Redalpine and First Star Ventures
Series A (2023): $13M led by Taiwania Capital, Debiopharm, and First Star Ventures
Key Investors in Genialis, Inc
First Star Ventures
First Star is an investment firm focused on supporting visionary, technical founders who are inventing the future through advanced technologies such as AI/ML, decentralization, edge computing, and techbio.
Debiopharm
Debiopharm Investment serves as the investment division of Debiopharm Group, focusing on safeguarding capital and generating consistent financial returns through strategic private equity and real estate holdings.
Redalpine
Redalpine is a thesis-driven venture capital firm with expertise in software and science, providing hands-on support to highly technical companies aiming to disrupt traditional industries.
What's next for Genialis, Inc?
With this latest infusion of capital, Genialis is poised to scale its operations and deepen its strategic partnerships within the pharmaceutical industry. The focus will likely shift toward expanding the utility of their platform in late-stage clinical trials, where the precision of patient selection is paramount to regulatory success. As the company continues to refine its AI-driven predictive capabilities, it is well-positioned to capture a larger share of the precision medicine market, potentially setting new industry standards for how oncology treatments are developed and validated. Future milestones will likely involve the integration of broader genomic datasets and the potential for licensing their therapeutic intelligence platform to major global biopharma entities.
See full Genialis, Inc company page
